STXBP2

Across TCGA pan-cancer cohorts, STXBP2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated STXBP2 data layer compared with 29 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher STXBP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated STXBP2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LUAD, COAD, and CCRCC are the cancer types where STXBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.724	0.920	.001	35	view →
COAD	DFS	Tertile	II,III,IV	0.845	1.000	.028	18	view →
CCRCC	DFS	Median	All	0.636	0.856	.003	16	view →
LSCC	OS	Median	All	0.918	0.716	.003	13	view →
PDAC	DFS	Tertile	II,III,IV	0.802	0.668	.015	8	view →
GBM	DFS	Quartile	All	0.135	0.343	.021	5	view →
OV	DFS	Tertile	All	0.703	1.000	.048	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

STXBP2–LUAD (OS)

Open the LUAD breakdown →